Aurore Perrot (A Perrot)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 60

Top Venues

Blood

British journal of haematology

Leukemia & lymphoma

Blood cancer journal

Université Toulouse III - Paul Sabatier

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Université Toulouse III - Paul Sabatier Sep 02 2019

France

Assistant professor :: Hematology IUCT

Publications

P Lebreton, F Lachenal, S Bouillie, G M Pica, H Aftisse, L Pascal, Lydiane Mordier, M Macro, N Johnson, S Harel, M Fernandez, B De Renzis, B Lioure, A Lazareth, M Javelot, C Louni, A Huart, Aurore Perrot
Teclistamab for relapsed refractory multiple myeloma patients on dialysis. British journal of haematology (2024)
Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot, Lionel Karlin, Murielle Roussel, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Marie-Lorraine Chretien, Kamel Laribi, Claire Dingremont, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Alberto Santagostino, Margaret Macro, Emmanuelle Bourgeois, Frederique Orsini-Piocelle, Julie Gay, Benoit Bareau, Noemie Bigot, François Vergez, Pierre Lebreton, Reza Tabrizi, Agathe Waultier-Rascalou, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Thorsten Braun, Florence Lachenal, Selim Corm, Celine Kennel, Rakiba Belkhir, Jean-Sebastien Bladé, Bertrand Joly, Valentine Richez-Olivier, Helene Gardeney, Helene Demarquette, Daniela Robu-Cretu, Laurent Garderet, Muriel Newinger-Porte, Amine Kasmi, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj, Cyrille Touzeau, Mohamad Mohty, Salomon Manier, Philippe Moreau, Hervé Avet-Loiseau, Jill Corre, Thierry Facon
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature medicine 30 (8) (2024)
Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, Aurore Perrot, Saad Z Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K Nooka, Thomas G Martin, Lionel Karlin, Xavier Leleu, Nizar J Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca I Verona, Suzette Girgis, Xin Miao, Clarissa Uhlar, Katherine Chastain, Alfred L Garfall
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma (2024)
Anaïs Schavgoulidze, Jill Corre, Mehmet K Samur, Celine Mazzotti, Luka Pavageau, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Margaret Macro, Karim Belhadj, Murielle Roussel, Sabine Brechignac, Lydia Montes, Denis Caillot, Laurent Frenzel, Philippe Rey, Jean Marc Schiano De Colella, Thomas Chalopin, Caroline Jacquet, Valentine Richez, Frederique Orsini Piocelle, Jean Fontan, Salomon Manier, Ludovic Martinet, Adam Sciambi, Mohamad Mohty, Hervé Avet-Loiseau
RAS/RAFlandscape in monoclonal plasma cell conditions. Blood (2024)
Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot, Lionel Karlin, Murielle Roussel, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Marie-Lorraine Chretien, Kamel Laribi, Claire Dingremont, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Alberto Santagostino, Margaret Macro, Emmanuelle Bourgeois, Frederique Orsini-Piocelle, Julie Gay, Benoit Bareau, Noemie Bigot, François Vergez, Pierre Lebreton, Reza Tabrizi, Agathe Waultier-Rascalou, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Thorsten Braun, Florence Lachenal, Selim Corm, Celine Kennel, Rakiba Belkhir, Jean-Sebastien Bladé, Bertrand Joly, Valentine Richez-Olivier, Helene Gardeney, Helene Demarquette, Daniela Robu-Cretu, Laurent Garderet, Muriel Newinger-Porte, Amine Kasmi, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj, Cyrille Touzeau, Mohamad Mohty, Salomon Manier, Philippe Moreau, Hervé Avet-Loiseau, Jill Corre, Thierry Facon
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature medicine 30 (8) (2024)
Anais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, Celine Mazzotti, Luka Pavageau, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Margaret Macro, Karim Belhadj, Murielle Roussel, Sabine Brechignac, Lydia Montes, Denis Caillot, Laurent Frenzel, Philippe Rey, Jean Marc Schiano De Colella, Thomas Chalopin, Caroline Jacquet, Valentine Richez, Frederique Orsini-Piocelle, Jean Fontan, Salomon Manier, Ludovic Martinet, Adam Sciambi, Mohamad Mohty, Herve Avet-Loiseau
RAS/RAF landscape in monoclonal plasma cell conditions. Blood 144 (2) (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma (2024)
B Ferment, J Lambert, D Caillot, I Lafon, L Karlin, A Lazareth, Cyrille Touzeau, Xavier Leleu, N Moya, S Harel, Aurore Perrot, Pierre Bories, L Vincent, S Lamure, Mohamad Mohty, F Malard, S Manier, I Yakoub-Agha, J-M Schiano De Colella, G Brisou, A Talbot, O Decaux, R Houot, S Le Gouill, N Bigot, T Facon, Jill Corre, Phillipe Moreau, Bertrand Arnulf, null null
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry. British journal of haematology (2024)
Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot, Lionel Karlin, Murielle Roussel, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Marie-Lorraine Chretien, Kamel Laribi, Claire Dingremont, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Alberto Santagostino, Margaret Macro, Emmanuelle Bourgeois, Frederique Orsini-Piocelle, Julie Gay, Benoit Bareau, Noemie Bigot, François Vergez, Pierre Lebreton, Reza Tabrizi, Agathe Waultier-Rascalou, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Thorsten Braun, Florence Lachenal, Selim Corm, Celine Kennel, Rakiba Belkhir, Jean-Sebastien Bladé, Bertrand Joly, Valentine Richez-Olivier, Helene Gardeney, Helene Demarquette, Daniela Robu-Cretu, Laurent Garderet, Muriel Newinger-Porte, Amine Kasmi, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj, Cyrille Touzeau, Mohamad Mohty, Salomon Manier, Philippe Moreau, Hervé Avet-Loiseau, Jill Corre, Thierry Facon
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature medicine (2024)
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Hervé Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau
Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma. Blood (2024)
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Hervé Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau
Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma. Blood (2024)
Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot, Lionel Karlin, Murielle Roussel, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Marie-Lorraine Chretien, Kamel Laribi, Claire Dingremont, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Alberto Santagostino, Margaret Macro, Emmanuelle Bourgeois, Frederique Orsini-Piocelle, Julie Gay, Benoit Bareau, Noemie Bigot, François Vergez, Pierre Lebreton, Reza Tabrizi, Agathe Waultier-Rascalou, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Thorsten Braun, Florence Lachenal, Selim Corm, Celine Kennel, Rakiba Belkhir, Jean-Sebastien Bladé, Bertrand Joly, Valentine Richez-Olivier, Helene Gardeney, Helene Demarquette, Daniela Robu-Cretu, Laurent Garderet, Muriel Newinger-Porte, Amine Kasmi, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj, Cyrille Touzeau, Mohamad Mohty, Salomon Manier, Philippe Moreau, Hervé Avet-Loiseau, Jill Corre, Thierry Facon
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature medicine (2024)
Anaïs Schavgoulidze, Jill Corre, Mehmet K Samur, Celine Mazzotti, Luka Pavageau, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Margaret Macro, Karim Belhadj, Murielle Roussel, Sabine Brechignac, Lydia Montes, Denis Caillot, Laurent Frenzel, Philippe Rey, Jean Marc Schiano De Colella, Thomas Chalopin, Caroline Jacquet, Valentine Richez, Frederique Orsini Piocelle, Jean Fontan, Salomon Manier, Ludovic Martinet, Adam Sciambi, Mohamad Mohty, Hervé Avet-Loiseau
RAS/RAFlandscape in monoclonal plasma cell conditions. Blood (2024)
Aurore Perrot, Murielle Roussel, Valerie Lauwers-Cances, Cyrille Hulin, Xavier Leleu, Cyrille Touzeau, Thierry Facon, Clara Mariette, Jean-Marc Schiano, Julie Gay, Lydiane Mordier, Dana Ranta, Amandine Huguet, Soraya Wuillème, Thomas Dejoie, Laure Devlamynck, Jill Corre, Hervé Avet-Loiseau, Phillipe Moreau, Michel Attal
Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03. British journal of haematology (2024)
Anais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, Celine Mazzotti, Luka Pavageau, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Margaret Macro, Karim Belhadj, Murielle Roussel, Sabine Brechignac, Lydia Montes, Denis Caillot, Laurent Frenzel, Philippe Rey, Jean Marc Schiano De Colella, Thomas Chalopin, Caroline Jacquet, Valentine Richez, Frederique Orsini-Piocelle, Jean Fontan, Salomon Manier, Ludovic Martinet, Adam Sciambi, Mohamad Mohty, Herve Avet-Loiseau
RAS/RAF landscape in monoclonal plasma cell conditions. Blood 144 (2) (2024)
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood 143 (20) (2024)
Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot, Lionel Karlin, Murielle Roussel, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Marie-Lorraine Chretien, Kamel Laribi, Claire Dingremont, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Alberto Santagostino, Margaret Macro, Emmanuelle Bourgeois, Frederique Orsini-Piocelle, Julie Gay, Benoit Bareau, Noemie Bigot, François Vergez, Pierre Lebreton, Reza Tabrizi, Agathe Waultier-Rascalou, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Thorsten Braun, Florence Lachenal, Selim Corm, Celine Kennel, Rakiba Belkhir, Jean-Sebastien Bladé, Bertrand Joly, Valentine Richez-Olivier, Helene Gardeney, Helene Demarquette, Daniela Robu-Cretu, Laurent Garderet, Muriel Newinger-Porte, Amine Kasmi, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj, Cyrille Touzeau, Mohamad Mohty, Salomon Manier, Philippe Moreau, Hervé Avet-Loiseau, Jill Corre, Thierry Facon
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature medicine 30 (8) (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma 65 (6) (2024)
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood 143 (20) (2024)
Eve Blanquart, Rüçhan Ekren, Bineta Rigaud, Marie Veronique Joubert, Virginie Baylot, Hélène Daunes, Marine Cuisinier, Marine Villard, Nadège Carrié, Celine Mazzotti, Liliana E Lucca, Aurore Perrot, Jill Corre, Thierry Walzer, Herve Avet-Loiseau, Pierre-Paul Axisa, Ludovic Martinet
NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in Multiple Myeloma. Blood (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma 65 (6) (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma 65 (6) (2024)
Somayya Noori, Charissa Wijnands, Pieter Langerhorst, Vincent Bonifay, Christoph Stingl, Cyrille Touzeau, Jill Corre, Aurore Perrot, Philippe Moreau, Hélène Caillon, Theo M Luider, Thomas Dejoie, Joannes F M Jacobs, Martijn M vanDuijn
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood cancer journal 13 (1) (2023)
Somayya Noori, Charissa Wijnands, Pieter Langerhorst, Vincent Bonifay, Christoph Stingl, Cyrille Touzeau, Jill Corre, Aurore Perrot, Philippe Moreau, Hélène Caillon, Theo M Luider, Thomas Dejoie, Joannes F M Jacobs, Martijn M vanDuijn
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood cancer journal 13 (1) (2023)
Mehmet K Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul-Hamid Bazarbachi, Raphael E Szalat, Masood A Shammas, Adam S Sperling, Paul G Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C Anderson, Herve Avet-Loiseau, Nikhil C Munshi
High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma. Blood (2023)
Mehmet K Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul-Hamid Bazarbachi, Raphael E Szalat, Masood A Shammas, Adam S Sperling, Paul G Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C Anderson, Herve Avet-Loiseau, Nikhil C Munshi
High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma. Blood (2023)
Enrique María Ocio, Aurore Perrot, Pierre Bories, Jesús San F Miguel, Igor W Blau, Lionel Karlin, Joaquin Martinez-Lopez, Song-Yau Wang, Sara Bringhen, Magda Marcatti, Maria-Victoria Mateos-Manteca, Paula Rodriguez Otero, Stefania Oliva, Axel Nogai, Nadia Le Roux, Liyan Dong, Sandrine Macé, Matthieu Gassiot, Thomas Fitzmaurice, Corina Oprea, Phillipe Moreau
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. Leukemia (2023)
Somayya Noori, Charissa Wijnands, Pieter Langerhorst, Vincent Bonifay, Christoph Stingl, Cyrille Touzeau, Jill Corre, Aurore Perrot, Philippe Moreau, Hélène Caillon, Theo M Luider, Thomas Dejoie, Joannes F M Jacobs, Martijn M vanDuijn
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood cancer journal 13 (1) (2023)
Kamel Laribi, Xavier Leleu, Nathalie Texier, Raphaël Germain, Cyrille Touzeau, Mohammad Hammoud, Alexandre Payssot, Samantha Schulmann, Ronan Le Calloch, Adrien Trebouet, Driss Chaoui, Selva David, Omar Benbrahim, Riad Benramdane, Anne Charvet-Rumpler, Christelle Jadeau, Eglantine Rouanet, Olivier Decaux, Aurore Perrot
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study. EJHaem 5 (1) (2023)
Kamel Laribi, Xavier Leleu, Nathalie Texier, Raphaël Germain, Cyrille Touzeau, Mohammad Hammoud, Alexandre Payssot, Samantha Schulmann, Ronan Le Calloch, Adrien Trebouet, Driss Chaoui, Selva David, Omar Benbrahim, Riad Benramdane, Anne Charvet-Rumpler, Christelle Jadeau, Eglantine Rouanet, Olivier Decaux, Aurore Perrot
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study. EJHaem 5 (1) (2023)
Anaïs Schavgoulidze, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Lydia Montes, Caroline Jacquet, Karim Belhadj, Sabine Brechignac, Laurent Frenzel, Thomas Chalopin, Philippe Rey, Jean-Marc Schiano de Collela, Mamoun Dib, Denis Caillot, Margaret Macro, Jean Fontan, Laure Buisson, Luka Pavageau, Murielle Roussel, Salomon Manier, Florent Malard, Ludovic Martinet, Hervé Avet-Loiseau, Jill Corre
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions. Blood cancer journal 13 (1) (2023)
Titouan Cazaubiel, Xavier Leleu, Aurore Perrot, Salomon Manier, Laure Buisson, Sabrina Maheo, Laura Do Souto Ferreira, Romain Lannes, Luka Pavageau, Cyrille Hulin, Jean-Pierre Marolleau, Laurent Voillat, Karim Belhadj, Marion Divoux, Borhane Slama, Sabine Brechignac, Margaret Macro, Anne-Marie Stoppa, Laurence Sanhes, Frédérique Orsini-Piocelle, Jean Fontan, Marie-Lorraine Chretien, Hélène Demarquette, Mohamad Mohty, Anaïs Schavgoulidze, Herve Avet-Loiseau, Jill Corre
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. Blood 139 (17) (2022)
Maria-Victoria Mateos-Manteca, Katja C Weisel, Valerio De Stefano, Hartmut Goldschmidt, Michel Delforge, Mohamad Mohty, Michele Cavo, Ravi Vij, Joanne Lindsey-Hill, Dominik Dytfeld, Emanuele Angelucci, Aurore Perrot, Reuben Benjamin, Niels W C J van de Donk, Enrique M Ocio, Christof Scheid, Francesca Gay, Wilfried Roeloffzen, Paula Rodriguez-Otero, Annemiek Broijl, Anna Potamianou, Caline Sakabedoyan, Maria Semerjian, Sofia Keim, Vadim Strulev, Jordan M Schecter, Martin Vogel, Robert Wapenaar, Tonia Nesheiwat, Jesús San F Miguel, Pieter Sonneveld, Hermann Einsele, Philippe Moreau
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 36 (5) (2022)
Romain Lannes, Mehmet Kemal Samur, Aurore Perrot, Celine Mazzotti, Marion Divoux, Titouan Cazaubiel, Xavier Leleu, Anaïs Schavgoulidze, Marie-Lorraine Chretien, Salomon Manier, Didier Adiko, Frederique Orsini-Piocelle, François Lifermann, Sabine Brechignac, Lauris Gastaud, Didier Bouscary, Margaret Macro, Alice Cleynen, Florent Malard, Nikhil C Munshi, Jill Corre, Herve Avet-Loiseau
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Salomon Manier, Laure Buisson, Sabrina Mahéo, Laura Do Souto Ferreira, Luka Pavageau, Cyrille Hulin, Jean-Pierre Marolleau, Laurent Voillat, Karim Belhadj, Marion Divoux, Borhane Slama, Sabine Brechignac, Margaret Macro, Anne Marie Stoppa, Laurence Sanhes, Frederique Orsini Piocelle, Jean Fontan, Marie-Lorraine Chretien, Hélène Demarquette, Mohamad Mohty, Herve Avet-Loiseau, Jill Corre
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood (2022)
Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Herve Avet-Loiseau, Jill Corre, Michel Attal
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood 139 (18) (2022)
Aurore Perrot
How I Treat Frontline Transplant-eligible Multiple Myeloma. Blood (2021)
Jill Corre, Aurore Perrot, Cyrille Hulin, Denis Caillot, Anne-Marie Stoppa, Thierry Facon, Xavier Leleu, Mamoun Dib, Lionel Karlin, Philippe Moreau, Mohamad Mohty, Clara Mariette, Jean Fontan, Jean-Pierre Marolleau, Hélène Demarquette, Borane Slama, Laurent Voillat, Margaret Macro, Frédérique Orsini-Piocelle, Sabine Brechignac, Philippe Rey, Philippe Collet, Mourad Tiab, Karim Belhadj, François Lifermann, Lauriane Clement-Filliatre, Claudine Sohn, Valentine Richez, Hervé Avet-Loiseau, null null
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. Leukemia 35 (12) (2021)
Anaïs Schavgoulidze, Titouan Cazaubiel, Aurore Perrot, Hervé Avet-Loiseau, Jill Corre
Multiple Myeloma: Heterogeneous in Every Way. Cancers 13 (6) (2021)
Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, René-Olivier Casasnovas, Delphine Nollet, Damien Roosweil, Sylvie Chevret, Véronique Leblond
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood advances 5 (9) (2021)
Alexis Caulier, Murielle Roussel, Pierre Morel, Naelle Lombion, Benoit Branco, Jean Galtier, Cyrille Hulin, Aurore Perrot, Valentine Richez, Anne-Victoire Michaud-Robert, Cyrille Touzeau, Chantal Doyen, Clara Mariette, Denis Caillot, Stephanie Harel, Pascal Lenain, Sarah Ivanoff, Jean Fontan, Anne Marie Stoppa, Salomon Manier, Laurent Garderet, Xavier Leleu, Jean-Pierre Marolleau, Bertrand Arnulf, Hervé Avet-Loiseau, Bruno Royer
EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE. Blood (2021)
Joseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, Ivan Spicka, Ravi Vij, Jeffrey Zonder, Djordje Atanackovic, Nashat Gabrail, Thomas G Martin, Aurore Perrot, Samira Bensfia, Qilong Weng, Claire Brillac, Dorothée Semiond, Sandrine Macé, Kathryn P Corzo, Xavier Leleu
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood cancer journal 11 (5) (2021)
Jean Baptiste Rieu, Aurore Perrot, Ines Vergnolle, Anais Schavgoulidze, Jill Corre
Multiple myeloma with hungry plasma cells. British journal of haematology 193 (3) (2021)
Paul Gerard Richardson, Aurore Perrot, Hiroyuki Takamatsu, null null
Revised international staging system allocation in the ICARIA-MM study: Practical challenges and impact on outcome. EJHaem 3 (1) (2021)
Simon James Harrison, Aurore Perrot, Adrian Alegre, David Simpson, Ming Chung Wang, Andrew Spencer, Sosana Delimpasi, Cyrille Hulin, Kazutaka Sunami, Thierry Facon, Philip Vlummens, Kwee L Yong, Frank Campana, Marlène Inchauspé, Sandrine Macé, Marie-Laure Risse, Helgi van de Velde, Paul Gerard Richardson
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. British journal of haematology 194 (1) (2021)
Orancie Alcouffe, Vincent Mémier, Frederique Dubois-Galopin, Aurore Perrot, Jill Corre, Jean Baptiste Rieu
Double-hit multiple myeloma with atypical "faggot" cells. British journal of haematology (2021)
Arthur Bobin, Maéva Kyheng, Stéphanie Guidez, Cécile Gruchet-Merouze, Valentine Richez, Alain Duhamel, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, Nathalie Meuleman, Jean-Valère Malfuson, Pascal Bourquard, Pascal Lenain, Aurore Perrot, Murielle Roussel, Arnaud Jaccard, Marie-Odile Petillon, Karim Belhadj-Merzoug, Marie-Lorraine Chretien, Jean Fontan, Philippe Rodon, Anna Schmitt, Fritz Offner, Laurent Voillat, Sophie Cereja, Frédérique Kuhnowski, Sophie Rigaudeau, Olivier Decaux, Catherine Humbrecht-Kraut, Jamile Frayfer, Olivier Fitoussi, Damien Roos-Weil, Jean Claude Eisenmann, Véronique Dorvaux, Eric G Voog, Philippe Moreau, Hervé Avet-Loiseau, Cyrille Hulin, Thierry Facon, null null, Xavier Leleu
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma. Leukemia (2021)
Michele Cavo, Jesús San F Miguel, Saad Z Usmani, Katja C Weisel, Meletios A A Dimopoulos, Hervé Avet-Loiseau, Juan José Lahuerta, Nizar J Bahlis, Torben Plesner, Vania Tietsche de Moraes Hungria, Philippe Moreau, Maria-Victoria Mateos-Manteca, Aurore Perrot, Shinsuke Iida, Thierry Facon, Shaji K Kumar, Niels W C J van de Donk, Pieter Sonneveld, Andrew Spencer, Maria Krevvata, Christoph Heuck, Jianping Wang, Jon Ukropec, Rachel Kobos, Steven Sun, Mia Qi, Nikhil C Munshi
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. Blood (2021)
Jean Baptiste Rieu, Aurore Perrot, Francois Vergez, Laetitia Largeaud, Jill Corre
When dystrophic plasma cells do not recognize themselves in the mirror. EJHaem 1 (2) (2020)
Titouan Cazaubiel, Olga Mulas, Lydia Montes, Anaïs Schavgoulidze, Hervé Avet-Loiseau, Jill Corre, Aurore Perrot
Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers 12 (12) (2020)
Elena Zamagni, Cristina Nanni, Luca Dozza, Thomas Carlier, Clément Bailly, Paola Tacchetti, Annibale Versari, Stephane Chauvie, Andrea Gallamini, Barbara Gamberi, Denis Caillot, Francesca Patriarca, Margaret Macro, Mario Boccadoro, Laurent Garderet, Simona Barbato, Stefano Fanti, Aurore Perrot, Francesca Gay, Pieter Sonneveld, Lionel Karlin, Michele Cavo, Caroline Bodet-Milin, Philippe Moreau, Françoise Kraeber-Bodéré
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (2) (2020)
Guilhem Tournaire, Cécile Conte, Aurore Perrot, Maryse Lapeyre Mestre, Fabien Despas
Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database. Vaccines 8 (4) (2020)
Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, Nelly Robillard, Cyrille Hulin, Marie-Lorraine Chretien, Thomas Dejoie, Sabrina Maheo, Anne-Marie Stoppa, Brigitte Pegourie, Lionel Karlin, Laurent Garderet, Bertrand Arnulf, Chantal Doyen, Nathalie Meuleman, Bruno Royer, Jean-Richard Eveillard, Lotfi Benboubker, Mamoun Dib, Olivier Decaux, Arnaud Jaccard, Karim Belhadj, Sabine Brechignac, Brigitte Kolb, Cecile Fohrer, Mohamad Mohty, Margaret Macro, Paul G Richardson, Victoria Carlton, Martin Moorhead, Tom Willis, Malek Faham, Kenneth C Anderson, Jean-Luc Harousseau, Xavier Leleu, Thierry Facon, Philippe Moreau, Michel Attal, Hervé Avet-Loiseau, Nikhil Munshi
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132 (23) (2018)
Emilio Iannitto, Monica Bellei, Sandy Amorim, Andrés J M Ferreri, Luigi Marcheselli, Marina Cesaretti, Corinne Haioun, Salvatrice Mancuso, Krimo Bouabdallah, Remy Gressin, Claudio Tripodo, Alexandra Traverse-Glehen, Lucile Baseggio, Simonetta Zupo, Caterina Stelitano, Barbara Castagnari, Caterina Patti, Isabel Alvarez, Anna Marina Liberati, Michele Merli, Guido Gini, Maria Giuseppina Cabras, Jean Dupuis, Benoit Tessoulin, Aurore Perrot, Francesca Re, Francesca Palombi, Alessandro Gulino, Emanuele Zucca, Massimo Federico, Catherine Thieblemont
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British journal of haematology 183 (5) (2018)
Laurent Garderet, Frederique Kuhnowski, Benoit Berge, Murielle Roussel, Martine Escoffre-Barbe, Ingrid Lafon, Thierry Facon, Xavier Leleu, Lionel Karlin, Aurore Perrot, Philippe Moreau, Gerald Marit, Anne-Marie Stoppa, Bruno Royer, Carine Chaleteix, Mourad Tiab, Carla Araujo, Pascal Lenain, Margaret Macro, Eric Voog, Lofti Benboubker, Olivier Allangba, Eric Jourdan, Frederique Orsini-Piocelle, Sabine Brechignac, Jean-Richard Eveillard, Karim Belhadj, Marc Wetterwald, Brigitte Pegourie, Arnaud Jaccard, Jean-Claude Eisenmann, Sylvie Glaisner, Mohamad Mohty, Cyrille Hulin, Herve Avet Loiseau, Claire Mathiot, Michel Attal
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood 132 (24) (2018)
Karine Augeul-Meunier, Marie-Lorraine Chretien, Anne-Marie Stoppa, Lionel Karlin, Lofti Benboubker, Jose Miguel Torregrosa Diaz, Mohamad Mohty, Ibrahim Yakoub-Agha, Jacques-Olivier Bay, Aurore Perrot, Claude-Eric Bulabois, Anne Huynh, Mélanie Mercier, Laurent Frenzel, Hervé Avet-Loiseau, Régis Peffault de Latour, Jérôme Cornillon
Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Bone marrow transplantation 53 (6) (2018)
Lauriane Filliatre-Clement, Julien Broseus, Marc Muller, Kossar Hosseini, Christine Rotonda, Luciane Schirmer, Gabrielle Roth-Guepin, Caroline Bonmati, Pierre Feugier, Marie Christine Bene, Aurore Perrot
Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia? Hematological oncology 37 (1) (2018)
Alice Cleynen, Mehmet Samur, Aurore Perrot, Laure Buisson, Sabrina Maheo, Mariateresa Fulciniti, Michel Attal, Nikhil Munshi, Hervé Avet-Loiseau, Jill Corre
Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). Blood 132 (26) (2018)
Clément Bailly, Thomas Carlier, Bastien Jamet, Thomas Eugene, Cyrille Touzeau, Michel Attal, Cyrille Hulin, Thierry Facon, Xavier Leleu, Aurore Perrot, Laurent Garderet, Margaret Macro, Denis Caillot, Philippe Moreau, Françoise Kraeber-Bodéré, Caroline Bodet-Milin
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (21) (2018)

Aurore Perrot.css-eqlu8i{font-size:small;padding-left:4px;} (A Perrot)

Publication Activity (10 Years)

Top Topics

Top Venues

Aurore Perrot (A Perrot)